Join our daily newsletter At The Bell to receive exclusive market insights
- Medical tech developer ImpediMed (IPD) is wrapping up a six-year trial and getting ready to submit the long-awaited results
- With the final patient check-ups now complete, investigators are closing up the trial’s 10 participating sites and have begun compiling data
- The trial is focussed on reducing breast cancer-related lymphoedema by measuring extra-cellular fluid using ImpediMed’s bioimpedance spectroscopy technology
- Investigators expect the final trial manuscript to be submitted for initial journal review by the end of February this year
- ImpediMed closed in the grey for 13 cents per share
Medical tech developer ImpediMed (IPD) is wrapping up a six-year trial and getting ready to submit the long-awaited results.
All of the trial’s 1100 patients have now finished their planned treatment and returned for their final follow-up examinations. Investigators will now close up the trial’s 10 participating sites and begin compiling data that will make up the final paper.
The trial is focussed on reducing breast cancer-related lymphoedema by measuring patient’s extra-cellular fluid using ImpediMed’s bioimpedance spectroscopy technology. The trial is testing the company’s L-Dex technology against standard tape measurements to hopefully demonstrate improved subclinical detection of extracellular fluid accumulation.
Early testing has already shown potentially fruitful results for ImpediMed’s technology but have yet to be peer reviewed.
Managing Director and CEO of ImpediMed Richard Carreon said the company was pleased to reach this important milestone.
“We believe the release of the results of the PREVENT trial, together with the recent meta-analysis results, will again further our case with both the NCCN and Private Payors,” he added.
With the last patient follow-up now complete, investigators expect the final trial manuscript to be submitted for initial journal review by the end of February this year.
News of the trial nearing completion marks a positive start to 2021 for ImpediMed and follows a rocky time on the ASX last year. After plunging more than 75 per cent in the opening months of last year, ImpediMed staged a tentative recovery and closed out the year around 25 per cent down on its January 2020 levels.
In trading on Monday, ImpediMed closed in the grey for 13 cents per share.
